Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
What does it do?
Lonza is a Swiss company that acts as a behind-the-scenes manufacturer for drug companies. Think of it this way: when a biotech startup invents a promising new medicine, they often don't have the factories or expertise to actually make it at scale — so they hire Lonza to do it for them. Lonza builds, runs, and manages the manufacturing process for everything from cancer drugs to cell therapies. You've probably never heard of them, but there's a good chance a medicine you've taken was made in one of their facilities.
The pharmaceutical industry is in the middle of a biologics boom — a shift toward complex medicines made from living cells rather than simple chemicals — and Lonza is one of the few companies in the world with the expertise and scale to manufacture them. As GLP-1 weight-loss drugs, cancer immunotherapies, and gene therapies flood the pipeline, drug companies need trusted manufacturing partners urgently. Lonza sits right at that bottleneck.
How does it make money?
Lonza makes money by charging pharmaceutical and biotech clients fees to develop and manufacture their drugs. Its largest segment, Integrated Biologics, handles complex biological medicines like antibodies and cell therapies, which command premium pricing. A smaller segment, Advanced Synthesis, covers more traditional chemical drug ingredients, while Specialized Modalities handles cutting-edge treatments like gene therapy. With $6.5 billion in annual revenue, most of it comes from long-term contracts that give Lonza predictable, recurring income.
Why do investors care?
The investment story is about Lonza being a picks-and-shovels play on the entire drug industry — meaning it profits no matter which individual drug wins, as long as pharma keeps growing. Demand for outsourced drug manufacturing is rising because even the biggest drug companies find it cheaper to hire specialists than build their own factories. For the thesis to play out, Lonza needs to keep filling its manufacturing capacity with new client contracts, maintain its pricing power, and successfully expand into newer modalities like cell and gene therapy.
Deep Dive
MemberA full investor briefing on Lonza Group AG — history, leadership, risks, and outlook.